This study aims to assess whether giving magnesium sulfate compared to placebo to women at risk of preterm birth between 30-34 weeks reduces the risk of death or cerebral palsy in children at two years. The study will randomly assign over 1600 women to receive either magnesium sulfate or placebo. The primary outcome measured will be death or cerebral palsy in children at two years. Previous studies have shown magnesium sulfate may reduce the risk of cerebral palsy in preterm infants, but the benefits at later gestational ages are uncertain, motivating this clinical trial.
The document discusses guidelines for using magnesium sulfate to reduce the risk of cerebral palsy in preterm infants. It describes protocols for magnesium sulfate administration before imminent preterm birth between 23-33 weeks gestation. Magnesium sulfate is thought to exert neuroprotective effects through vasodilation, anti-inflammatory actions, and modulation of NMDA receptors. Larger clinical trials and meta-analyses support the efficacy and safety of magnesium sulfate for reducing cerebral palsy.
The document discusses evidence that magnesium sulfate administered to mothers at risk of preterm birth reduces the risk of cerebral palsy in infants. Several large randomized controlled trials and meta-analyses involving over 15,000 women found magnesium sulfate decreased the risk of cerebral palsy without increasing mortality. The number needed to treat to prevent one case of cerebral palsy is estimated at 63 women. The document also describes a modified magnesium sulfate neuroprotection protocol used at Riverside Hospital for imminent preterm deliveries between 23 and 33 weeks.
This randomized controlled trial tested the effects of antibiotics (erythromycin and co-amoxiclav) on neonatal outcomes in women with preterm prelabor rupture of membranes (pPROM). 4826 women with pPROM were assigned to receive erythromycin, co-amoxiclav, both antibiotics, or placebo for 10 days or until delivery. Erythromycin was associated with reductions in the composite outcome of neonatal death, chronic lung disease or major brain abnormality compared to placebo, as well as prolongation of pregnancy and reductions in other neonatal complications. Co-amoxiclav provided no benefits and was associated with an increased risk of necrotizing enterocolitis. Eryth
Optimizing The outcome of Threatened Abortion Dr Sharda Jain Lifecare Centre
- Around 70% of conceptions are lost prior to live birth, with 30% lost before implantation and 30% after implantation but before a missed period. Threatened abortion refers to vaginal bleeding or pain, or both, in early pregnancy when the cervical os remains closed.
- Studies have shown that counseling reduces adverse psychological effects from miscarriage. Treatment with dydrogesterone has been shown to reduce pregnancy loss in threatened abortion during the first trimester compared to placebo or no treatment. However, treatment with vaginal progesterone compared to placebo appears to have little effect on reducing miscarriage rates.
- Meta-analyses of multiple randomized controlled trials found that treatment with dydrogesterone for threatened miscarriage significantly reduced miscarriage
The document provides an update on contraception. It discusses various contraceptive methods including levonorgestrel emergency contraception, subcutaneous DMPA, and the lactational amenorrhea method. It addresses common misconceptions about contraceptive effectiveness and safety. The document is divided into multiple rounds testing knowledge of contraceptive guidelines through true/false and multiple choice questions.
This document summarizes the antiphospholipid antibody syndrome (APS). It discusses that APS is characterized by the presence of antiphospholipid antibodies (aPLs) along with clinical manifestations such as vascular thrombosis or pregnancy morbidity. The diagnostic criteria for APS requires at least one clinical feature and one laboratory feature present on two or more occasions at least 12 weeks apart. Common obstetric complications of APS include recurrent miscarriage, fetal loss, severe preeclampsia before 34 weeks gestation, and severe placental insufficiency. The pathogenesis of APS is thought to involve thrombosis, defective placentation, and local inflammatory events.
Experience of Metformin Use in Gestational Diabetes: Contribution to the DebateApollo Hospitals
This article discusses the experience of using metformin to treat gestational diabetes at a hospital in the UK. It summarizes the results of a retrospective study of 54 women treated with metformin between 2006-2009. The study found metformin was well tolerated with few adverse maternal or fetal outcomes. Only 7.4% discontinued metformin and 22% required supplemental insulin. Preeclampsia occurred in 3.7% of cases. Fetal outcomes like macrosomia and neonatal complications were also low. The article contributes to the debate around using metformin as an alternative to insulin for treating gestational diabetes.
1. Selective progesterone receptor modulators (SPRMs) are a class of drugs that act as agonists or antagonists of the progesterone receptor in a tissue-selective manner.
2. Several SPRMs are discussed in the document, including mifepristone, ulipristal acetate, telapristone, and asoprisnil, which are being studied for uses like emergency contraception and treatment of uterine fibroids.
3. Clinical trials have compared the effectiveness of different SPRMs to other medications for emergency contraception and found them to be similarly effective while also having fewer side effects in some cases. SPRMs are also being researched for their potential mechanisms of action and effects on tissues like
The document discusses guidelines for using magnesium sulfate to reduce the risk of cerebral palsy in preterm infants. It describes protocols for magnesium sulfate administration before imminent preterm birth between 23-33 weeks gestation. Magnesium sulfate is thought to exert neuroprotective effects through vasodilation, anti-inflammatory actions, and modulation of NMDA receptors. Larger clinical trials and meta-analyses support the efficacy and safety of magnesium sulfate for reducing cerebral palsy.
The document discusses evidence that magnesium sulfate administered to mothers at risk of preterm birth reduces the risk of cerebral palsy in infants. Several large randomized controlled trials and meta-analyses involving over 15,000 women found magnesium sulfate decreased the risk of cerebral palsy without increasing mortality. The number needed to treat to prevent one case of cerebral palsy is estimated at 63 women. The document also describes a modified magnesium sulfate neuroprotection protocol used at Riverside Hospital for imminent preterm deliveries between 23 and 33 weeks.
This randomized controlled trial tested the effects of antibiotics (erythromycin and co-amoxiclav) on neonatal outcomes in women with preterm prelabor rupture of membranes (pPROM). 4826 women with pPROM were assigned to receive erythromycin, co-amoxiclav, both antibiotics, or placebo for 10 days or until delivery. Erythromycin was associated with reductions in the composite outcome of neonatal death, chronic lung disease or major brain abnormality compared to placebo, as well as prolongation of pregnancy and reductions in other neonatal complications. Co-amoxiclav provided no benefits and was associated with an increased risk of necrotizing enterocolitis. Eryth
Optimizing The outcome of Threatened Abortion Dr Sharda Jain Lifecare Centre
- Around 70% of conceptions are lost prior to live birth, with 30% lost before implantation and 30% after implantation but before a missed period. Threatened abortion refers to vaginal bleeding or pain, or both, in early pregnancy when the cervical os remains closed.
- Studies have shown that counseling reduces adverse psychological effects from miscarriage. Treatment with dydrogesterone has been shown to reduce pregnancy loss in threatened abortion during the first trimester compared to placebo or no treatment. However, treatment with vaginal progesterone compared to placebo appears to have little effect on reducing miscarriage rates.
- Meta-analyses of multiple randomized controlled trials found that treatment with dydrogesterone for threatened miscarriage significantly reduced miscarriage
The document provides an update on contraception. It discusses various contraceptive methods including levonorgestrel emergency contraception, subcutaneous DMPA, and the lactational amenorrhea method. It addresses common misconceptions about contraceptive effectiveness and safety. The document is divided into multiple rounds testing knowledge of contraceptive guidelines through true/false and multiple choice questions.
This document summarizes the antiphospholipid antibody syndrome (APS). It discusses that APS is characterized by the presence of antiphospholipid antibodies (aPLs) along with clinical manifestations such as vascular thrombosis or pregnancy morbidity. The diagnostic criteria for APS requires at least one clinical feature and one laboratory feature present on two or more occasions at least 12 weeks apart. Common obstetric complications of APS include recurrent miscarriage, fetal loss, severe preeclampsia before 34 weeks gestation, and severe placental insufficiency. The pathogenesis of APS is thought to involve thrombosis, defective placentation, and local inflammatory events.
Experience of Metformin Use in Gestational Diabetes: Contribution to the DebateApollo Hospitals
This article discusses the experience of using metformin to treat gestational diabetes at a hospital in the UK. It summarizes the results of a retrospective study of 54 women treated with metformin between 2006-2009. The study found metformin was well tolerated with few adverse maternal or fetal outcomes. Only 7.4% discontinued metformin and 22% required supplemental insulin. Preeclampsia occurred in 3.7% of cases. Fetal outcomes like macrosomia and neonatal complications were also low. The article contributes to the debate around using metformin as an alternative to insulin for treating gestational diabetes.
1. Selective progesterone receptor modulators (SPRMs) are a class of drugs that act as agonists or antagonists of the progesterone receptor in a tissue-selective manner.
2. Several SPRMs are discussed in the document, including mifepristone, ulipristal acetate, telapristone, and asoprisnil, which are being studied for uses like emergency contraception and treatment of uterine fibroids.
3. Clinical trials have compared the effectiveness of different SPRMs to other medications for emergency contraception and found them to be similarly effective while also having fewer side effects in some cases. SPRMs are also being researched for their potential mechanisms of action and effects on tissues like
Progynova is used as a Hormone Replacement Therapy (HRT) to alleviate the oestrogen deficiency symptoms like such as hot flushes, sweats, sleep disturbances, depressive moods, irritability, dizziness, headaches as well as vaginal dryness and burning in peri- and postmenopausal women. This medicine is also used for prevention of postmenopausal osteoporosis in cases where other medicines are not suitable for the patient and are at risk of of fractures due to osteoporosis.
Depo Provera Contraceptive Injection (Medroxyprogesterone Acetate) is used to prevent pregnancy. This medicine works by preventing the growth and release of an egg (ovulation) during the menstrual cycle.
Depo-Provera CI (Medroxyprogesterone Acetate Injectable Suspension) The Swiss Pharmacy
Depo-Provera Contraceptive Injection (Medroxyprogesterone Acetate injectable Suspension) is a progestin indicated for use by females of reproductive potential to prevent pregnancy. It is also used to treat endometriosis, abnormal uterine bleeding, abnormal sexuality in males, and certain types of cancer.
This document discusses various methods for cervical ripening in induction of labor (IOL) for women with a scarred uterus. It describes pharmacological methods like oxytocin, prostaglandins, and other agents as well as mechanical methods such as membrane stripping, amniotomy, and balloon catheters. Specific details are provided on the use of Foley catheters for cervical ripening, including their safety, efficacy, and advantages over prostaglandins for women with a prior cesarean delivery.
This document discusses repeated doses of antenatal corticosteroids for women at risk of preterm birth. It provides background on the benefits of corticosteroids in reducing preterm birth complications. While repeated doses are associated with better neonatal lung function, there is no significant reduction in severe respiratory distress or brain injuries. Repeated doses may cause intrauterine growth restriction. The document recommends repeating a single rescue dose or course only if 7 days have passed since the initial dose and the woman remains at risk of preterm labor.
This document provides guidelines for managing preterm labor, including recommendations on diagnosing preterm labor, treating it with tocolytic drugs and antibiotics, administering antenatal corticosteroids, and special clinical situations. It recommends using ultrasonography and fetal fibronectin testing to determine risk of preterm delivery. For treatment, it finds limited benefit from tocolytic drugs and no clear preferred drug. Antibiotics are not recommended solely to prevent preterm delivery. Antenatal corticosteroids significantly reduce neonatal respiratory issues and mortality.
Dexamethasone in Prevention of Respiratory Morbidity in Elective Caesarean S...احمد عبدالراضى
Dexamethasone in Prevention of Respiratory Morbidity in
Elective Caesarean Section in Term Fetus
Qena University Hospital Experience
By
Ahmed Abdel-Rady Ali
(M.B, B.Ch.)
Resident physician in obstetrics and gynecology
Qena University Hospital
South Valley University
Calendario 12 curso intensivo puesta en marcha de un negocio online 2014-1Interlat
Este documento presenta el calendario y detalles de un curso intensivo de 12 horas sobre la puesta en marcha de un negocio online. Se ofrecerá tanto de forma presencial en Bogotá y Medellín, Colombia, como de forma virtual a través de webinars. El curso se llevará a cabo del 20 al 26 de febrero de 2014 y será dictado por Carlos Lluberes de la República Dominicana.
This document certifies that an individual has been evaluated and granted the credential of Project Management Professional (PMP) by demonstrating experience, knowledge, and performance in defining, overseeing projects and resources to achieve organizational objectives. It is signed by the President and CEO as well as the Chair of the Board of Directors of the certifying institute and specifies the PMP number, original grant date, and expiration date of the credential.
Calendario - 14 Curso Intensivo SEO para Comercio Electrónico 2014-1Interlat
Este documento presenta el calendario y la información logística para un curso intensivo de 14 horas sobre SEO para comercio electrónico que se llevará a cabo en Bogotá y Medellín, Colombia entre el 6 y 12 de marzo de 2014. El curso será impartido por Juan Sebastián Delgado y combinará clases presenciales con seminarios virtuales. Los asistentes recibirán una certificación si asisten al menos al 80% de las clases y completan las actividades académicas.
The article analyzes the cost-effectiveness of administering magnesium sulphate to patients at risk of preterm birth before 32 weeks gestation. It finds that from both health system and societal perspectives, magnesium sulphate administration is either cost-saving or very cost-effective for preventing cerebral palsy cases and improving quality-adjusted life years. For patients with imminent preterm birth, magnesium sulphate is a dominant, cost-effective strategy regardless of perspective or effectiveness measure used. For those with threatened preterm birth, it is dominant from a societal perspective and likely cost-effective from a health system view.
El documento define y describe los diferentes tipos de conexiones a Internet, incluyendo ADSL, fibra óptica, vía satélite, dial-up, banda ancha, cable módem, acceso inalámbrico y otras conexiones inalámbricas. Define cada tipo de conexión y explica sus características, velocidades, alcances y cómo funcionan. El objetivo es proporcionar una descripción general de las opciones disponibles para acceder a Internet.
George Simón Ohm fue un físico alemán que descubrió la ley que lleva su nombre en 1827. La Ley de Ohm establece que la corriente eléctrica que fluye a través de un conductor es directamente proporcional a la diferencia de potencial aplicada e inversamente proporcional a la resistencia del conductor. Ohm publicó sus hallazgos en un folleto titulado "El circuito galvánico examinado matemáticamente".
Calendario 13 Curso Intensivo Social E-Commerce 2014-1Interlat
Este documento presenta el calendario y detalles de un curso intensivo de 13 horas sobre Social E-Commerce que se llevará a cabo en Bogotá y Medellín, Colombia, así como de forma virtual, entre el 27 de febrero y el 5 de marzo de 2014. El curso será dictado por Pablo Di Meglio de Argentina e incluirá 8 horas presenciales y 4 horas virtuales.
1) Magnesium sulfate has been shown to provide neuroprotective effects for extremely premature infants by reducing cerebral injury and cell death.
2) While some studies found magnesium sulfate to be neuroprotective, others did not find sustainable effects, so more randomized studies were conducted.
3) A Cochrane review of 5 randomized trials found magnesium sulfate significantly reduced the risk of cerebral palsy in premature infants without increasing mortality risks for mother or infant.
This editorial discusses a recent randomized controlled trial that evaluated the use of bortezomib plus melphalan and prednisone compared to melphalan and prednisone alone for the initial treatment of multiple myeloma in patients who were not eligible for stem cell transplantation. The trial found that the combination of bortezomib provided superior outcomes, including higher response rates and longer duration of response. However, the editorial cautions that to effectively apply these results, comparisons need to be made to other available treatment options, long-term outcomes need to be evaluated, and toxic effects on quality of life considered. Overall progress is being made in multiple myeloma treatment, but further research is still needed.
This study protocol describes a randomized controlled trial to assess whether magnesium sulfate compared to placebo administered to women at risk of preterm birth between 30-34 weeks reduces the risk of death or cerebral palsy in children at two years of age. The trial will randomize over 1676 women to receive either magnesium sulfate or placebo by IV infusion within 24 hours of planned or expected preterm birth. The primary outcome will be death or cerebral palsy in children at two years of age. The trial aims to provide evidence on whether the neuroprotective benefits of magnesium sulfate seen at earlier gestations apply at 30-34 weeks.
This Cochrane review examines the effects of magnesium sulfate given to women at risk of preterm birth to protect the fetus's brain. The review found that magnesium sulfate significantly reduced the risk of cerebral palsy in preterm infants by 32% and reduced substantial gross motor dysfunction by 39%. No significant effects were found for pediatric mortality or other neurological impairments. Magnesium sulfate was found to have minor side effects for mothers but no significant effects on major maternal complications. The review concludes that magnesium sulfate has a established neuroprotective role for preterm fetuses.
This Cochrane review examines whether magnesium sulfate administered to women at term protects the fetus from brain injury. The review included one small randomized controlled trial involving 135 women with mild preeclampsia. The trial found no significant differences in outcomes like Apgar scores or gestational age between infants whose mothers received magnesium sulfate or placebo. Maternal side effects like warmth and flushing were more common with magnesium sulfate, but serious side effects causing treatment cessation were not. Larger trials are still needed to determine if magnesium sulfate provides neuroprotective benefits for term infants.
The document discusses evidence that magnesium sulfate administered to mothers at risk of preterm birth reduces the risk of cerebral palsy in infants. Several large randomized controlled trials and meta-analyses involving over 15,000 women found magnesium sulfate decreased the risk of cerebral palsy without increasing mortality. The number needed to treat to prevent one case of cerebral palsy is estimated at 63 women. The document also describes a modified magnesium sulfate neuroprotection protocol used at Riverside Hospital for imminent preterm deliveries between 23 and 33 weeks.
This review examines the effectiveness of magnesium sulfate given to women at term to protect the fetus from brain injury and neurodevelopmental disabilities like cerebral palsy. The review included one randomized controlled trial with 135 women with mild preeclampsia at term. The trial found no significant differences in infant outcomes like Apgar scores or gestational age between the magnesium sulfate and placebo groups. Maternal side effects were more common with magnesium sulfate, but severe side effects causing treatment cessation were similar between groups. Larger trials are still needed to determine if magnesium sulfate provides neuroprotection for infants when administered at term.
This randomized controlled trial tested the effects of antibiotics (erythromycin and co-amoxiclav) on neonatal outcomes in women with preterm prelabor rupture of membranes (pPROM). 4826 women with pPROM were assigned to receive erythromycin, co-amoxiclav, both antibiotics, or placebo for 10 days or until delivery. Erythromycin was associated with reductions in the composite outcome of neonatal death, chronic lung disease or major brain abnormality compared to placebo, as well as prolongation of pregnancy and reductions in other neonatal complications. Co-amoxiclav was associated with prolongation of pregnancy but also an increased risk of necrotizing enterocolitis and did
Progynova is used as a Hormone Replacement Therapy (HRT) to alleviate the oestrogen deficiency symptoms like such as hot flushes, sweats, sleep disturbances, depressive moods, irritability, dizziness, headaches as well as vaginal dryness and burning in peri- and postmenopausal women. This medicine is also used for prevention of postmenopausal osteoporosis in cases where other medicines are not suitable for the patient and are at risk of of fractures due to osteoporosis.
Depo Provera Contraceptive Injection (Medroxyprogesterone Acetate) is used to prevent pregnancy. This medicine works by preventing the growth and release of an egg (ovulation) during the menstrual cycle.
Depo-Provera CI (Medroxyprogesterone Acetate Injectable Suspension) The Swiss Pharmacy
Depo-Provera Contraceptive Injection (Medroxyprogesterone Acetate injectable Suspension) is a progestin indicated for use by females of reproductive potential to prevent pregnancy. It is also used to treat endometriosis, abnormal uterine bleeding, abnormal sexuality in males, and certain types of cancer.
This document discusses various methods for cervical ripening in induction of labor (IOL) for women with a scarred uterus. It describes pharmacological methods like oxytocin, prostaglandins, and other agents as well as mechanical methods such as membrane stripping, amniotomy, and balloon catheters. Specific details are provided on the use of Foley catheters for cervical ripening, including their safety, efficacy, and advantages over prostaglandins for women with a prior cesarean delivery.
This document discusses repeated doses of antenatal corticosteroids for women at risk of preterm birth. It provides background on the benefits of corticosteroids in reducing preterm birth complications. While repeated doses are associated with better neonatal lung function, there is no significant reduction in severe respiratory distress or brain injuries. Repeated doses may cause intrauterine growth restriction. The document recommends repeating a single rescue dose or course only if 7 days have passed since the initial dose and the woman remains at risk of preterm labor.
This document provides guidelines for managing preterm labor, including recommendations on diagnosing preterm labor, treating it with tocolytic drugs and antibiotics, administering antenatal corticosteroids, and special clinical situations. It recommends using ultrasonography and fetal fibronectin testing to determine risk of preterm delivery. For treatment, it finds limited benefit from tocolytic drugs and no clear preferred drug. Antibiotics are not recommended solely to prevent preterm delivery. Antenatal corticosteroids significantly reduce neonatal respiratory issues and mortality.
Dexamethasone in Prevention of Respiratory Morbidity in Elective Caesarean S...احمد عبدالراضى
Dexamethasone in Prevention of Respiratory Morbidity in
Elective Caesarean Section in Term Fetus
Qena University Hospital Experience
By
Ahmed Abdel-Rady Ali
(M.B, B.Ch.)
Resident physician in obstetrics and gynecology
Qena University Hospital
South Valley University
Calendario 12 curso intensivo puesta en marcha de un negocio online 2014-1Interlat
Este documento presenta el calendario y detalles de un curso intensivo de 12 horas sobre la puesta en marcha de un negocio online. Se ofrecerá tanto de forma presencial en Bogotá y Medellín, Colombia, como de forma virtual a través de webinars. El curso se llevará a cabo del 20 al 26 de febrero de 2014 y será dictado por Carlos Lluberes de la República Dominicana.
This document certifies that an individual has been evaluated and granted the credential of Project Management Professional (PMP) by demonstrating experience, knowledge, and performance in defining, overseeing projects and resources to achieve organizational objectives. It is signed by the President and CEO as well as the Chair of the Board of Directors of the certifying institute and specifies the PMP number, original grant date, and expiration date of the credential.
Calendario - 14 Curso Intensivo SEO para Comercio Electrónico 2014-1Interlat
Este documento presenta el calendario y la información logística para un curso intensivo de 14 horas sobre SEO para comercio electrónico que se llevará a cabo en Bogotá y Medellín, Colombia entre el 6 y 12 de marzo de 2014. El curso será impartido por Juan Sebastián Delgado y combinará clases presenciales con seminarios virtuales. Los asistentes recibirán una certificación si asisten al menos al 80% de las clases y completan las actividades académicas.
The article analyzes the cost-effectiveness of administering magnesium sulphate to patients at risk of preterm birth before 32 weeks gestation. It finds that from both health system and societal perspectives, magnesium sulphate administration is either cost-saving or very cost-effective for preventing cerebral palsy cases and improving quality-adjusted life years. For patients with imminent preterm birth, magnesium sulphate is a dominant, cost-effective strategy regardless of perspective or effectiveness measure used. For those with threatened preterm birth, it is dominant from a societal perspective and likely cost-effective from a health system view.
El documento define y describe los diferentes tipos de conexiones a Internet, incluyendo ADSL, fibra óptica, vía satélite, dial-up, banda ancha, cable módem, acceso inalámbrico y otras conexiones inalámbricas. Define cada tipo de conexión y explica sus características, velocidades, alcances y cómo funcionan. El objetivo es proporcionar una descripción general de las opciones disponibles para acceder a Internet.
George Simón Ohm fue un físico alemán que descubrió la ley que lleva su nombre en 1827. La Ley de Ohm establece que la corriente eléctrica que fluye a través de un conductor es directamente proporcional a la diferencia de potencial aplicada e inversamente proporcional a la resistencia del conductor. Ohm publicó sus hallazgos en un folleto titulado "El circuito galvánico examinado matemáticamente".
Calendario 13 Curso Intensivo Social E-Commerce 2014-1Interlat
Este documento presenta el calendario y detalles de un curso intensivo de 13 horas sobre Social E-Commerce que se llevará a cabo en Bogotá y Medellín, Colombia, así como de forma virtual, entre el 27 de febrero y el 5 de marzo de 2014. El curso será dictado por Pablo Di Meglio de Argentina e incluirá 8 horas presenciales y 4 horas virtuales.
1) Magnesium sulfate has been shown to provide neuroprotective effects for extremely premature infants by reducing cerebral injury and cell death.
2) While some studies found magnesium sulfate to be neuroprotective, others did not find sustainable effects, so more randomized studies were conducted.
3) A Cochrane review of 5 randomized trials found magnesium sulfate significantly reduced the risk of cerebral palsy in premature infants without increasing mortality risks for mother or infant.
This editorial discusses a recent randomized controlled trial that evaluated the use of bortezomib plus melphalan and prednisone compared to melphalan and prednisone alone for the initial treatment of multiple myeloma in patients who were not eligible for stem cell transplantation. The trial found that the combination of bortezomib provided superior outcomes, including higher response rates and longer duration of response. However, the editorial cautions that to effectively apply these results, comparisons need to be made to other available treatment options, long-term outcomes need to be evaluated, and toxic effects on quality of life considered. Overall progress is being made in multiple myeloma treatment, but further research is still needed.
This study protocol describes a randomized controlled trial to assess whether magnesium sulfate compared to placebo administered to women at risk of preterm birth between 30-34 weeks reduces the risk of death or cerebral palsy in children at two years of age. The trial will randomize over 1676 women to receive either magnesium sulfate or placebo by IV infusion within 24 hours of planned or expected preterm birth. The primary outcome will be death or cerebral palsy in children at two years of age. The trial aims to provide evidence on whether the neuroprotective benefits of magnesium sulfate seen at earlier gestations apply at 30-34 weeks.
This Cochrane review examines the effects of magnesium sulfate given to women at risk of preterm birth to protect the fetus's brain. The review found that magnesium sulfate significantly reduced the risk of cerebral palsy in preterm infants by 32% and reduced substantial gross motor dysfunction by 39%. No significant effects were found for pediatric mortality or other neurological impairments. Magnesium sulfate was found to have minor side effects for mothers but no significant effects on major maternal complications. The review concludes that magnesium sulfate has a established neuroprotective role for preterm fetuses.
This Cochrane review examines whether magnesium sulfate administered to women at term protects the fetus from brain injury. The review included one small randomized controlled trial involving 135 women with mild preeclampsia. The trial found no significant differences in outcomes like Apgar scores or gestational age between infants whose mothers received magnesium sulfate or placebo. Maternal side effects like warmth and flushing were more common with magnesium sulfate, but serious side effects causing treatment cessation were not. Larger trials are still needed to determine if magnesium sulfate provides neuroprotective benefits for term infants.
The document discusses evidence that magnesium sulfate administered to mothers at risk of preterm birth reduces the risk of cerebral palsy in infants. Several large randomized controlled trials and meta-analyses involving over 15,000 women found magnesium sulfate decreased the risk of cerebral palsy without increasing mortality. The number needed to treat to prevent one case of cerebral palsy is estimated at 63 women. The document also describes a modified magnesium sulfate neuroprotection protocol used at Riverside Hospital for imminent preterm deliveries between 23 and 33 weeks.
This review examines the effectiveness of magnesium sulfate given to women at term to protect the fetus from brain injury and neurodevelopmental disabilities like cerebral palsy. The review included one randomized controlled trial with 135 women with mild preeclampsia at term. The trial found no significant differences in infant outcomes like Apgar scores or gestational age between the magnesium sulfate and placebo groups. Maternal side effects were more common with magnesium sulfate, but severe side effects causing treatment cessation were similar between groups. Larger trials are still needed to determine if magnesium sulfate provides neuroprotection for infants when administered at term.
This randomized controlled trial tested the effects of antibiotics (erythromycin and co-amoxiclav) on neonatal outcomes in women with preterm prelabor rupture of membranes (pPROM). 4826 women with pPROM were assigned to receive erythromycin, co-amoxiclav, both antibiotics, or placebo for 10 days or until delivery. Erythromycin was associated with reductions in the composite outcome of neonatal death, chronic lung disease or major brain abnormality compared to placebo, as well as prolongation of pregnancy and reductions in other neonatal complications. Co-amoxiclav was associated with prolongation of pregnancy but also an increased risk of necrotizing enterocolitis and did
This article discusses the use of magnesium sulfate (MgSO4) for treating severe preeclampsia and eclampsia. It summarizes evidence from the Magpie Trial showing MgSO4 significantly reduces the risk of eclampsia recurrence and maternal mortality compared to other anticonvulsants. The article reviews MgSO4 regimens, monitoring for toxicity, and the need for training health workers in developing countries on its proper use. It concludes increased availability and training on MgSO4 could help reduce eclampsia's contribution to maternal mortality.
- Preterm birth is defined as birth between 20-36 weeks of gestation. Preterm labor is diagnosed based on uterine contractions and cervical changes.
- Tests like fetal fibronectin and cervical length can help predict risk of preterm birth but have poor positive predictive value on their own.
- Antenatal corticosteroids between 24-34 weeks of gestation significantly reduce neonatal mortality and morbidity for preterm births within 7 days and should be considered routine.
- Magnesium sulfate before 32 weeks of gestation reduces the risk of cerebral palsy in surviving infants.
Neuroprotection strategies for newborns ,2018 - Dr Karthik Nageshkarthiknagesh
This document provides information about Dr. N. Karthik Nagesh, his qualifications and experience in neonatology. It then summarizes his presentation on strategies for perinatal neuroprotection in newborns. These include antenatal steroids, magnesium sulfate, delayed cord clamping, therapeutic hypothermia, caffeine, kangaroo care and investigational therapies like melatonin and erythropoietin. The goal is to help newborns, especially preterms and those with birth asphyxia, have intact survival by preventing brain injury. Future areas of research discussed include preventing preterm birth and better identifying babies at risk of hypoxic ischemic encephalopathy.
Dấu hiệu, nguyên nhân của mãn kinh sớm và cách điều trị | Venus GlobalVENUS
Trong những năm gần đây, mãn kinh sớm đang là một vấn đề khiến nhiều chị em lo lắng. Có rất nhiều nguyên nhân gây ra tình trạng mãn kinh sớm nó có thể do thói quen ăn uống, sinh hoạt ảnh hưởng đến nội tiết tố nữ và tứ đó gây ra mãn kinh. Trong bài viết này Venus sẽ cung cấp cho bạn toàn bộ thông tin về nguyên nhân, biểu hiện gây ra căn bệnh này để bạn đọc có cách phòng tránh cũng như điều trị kịp thời.
Nguồn: Trích https://venusglobal.com.vn/man-kinh-som/
#mãn_kinh_sớm
#dấu_hiệu_mãn_kinh_sớm
#cách_trị_mãn_kinh_sớm
#dấu_hiệu_của_mãn_kinh_sớm
#dau_hieu_cua_man_kinh_som
This document summarizes research on neuroprotection in preterm infants. It discusses how preterm infants under 30 weeks gestation are at high risk for brain damage from ischemia or infection. Preventing preterm birth and treating intrauterine infections early can reduce this risk. The document reviews evidence that magnesium administered to women at risk of preterm birth reduces rates of cerebral palsy and motor deficits in infants. Delaying umbilical cord clamping also reduces brain hemorrhaging. While stem cells show neuroprotective effects in animals, clinical trials are still needed.
This document discusses preventing preterm labour. It begins by providing statistics on the incidence of preterm birth in various locations. It then discusses the magnitude of the problem, highlighting the high costs of preterm birth. Several studies on outcomes of extremely preterm infants are summarized. The document is then organized into sections on primary, secondary, and tertiary prevention of preterm labour. Key points are made about various risk factors and diagnostic tools, as well as treatments such as progesterone, cerclage and antibiotics.
Screening for and treatment of asymptomatic bacteriuria in high-risk pregnant women reduces the risk of preterm birth. However, routine screening of all pregnant women in the first trimester with urine culture is not currently recommended due to the low prevalence of asymptomatic bacteriuria in the general pregnant population and the costs of universal screening.
Therapeutic startegies for human papillomavirus infection and associated cancersAdeniyiAkiseku
Human papillomavirus (HPV) infection is linked to development of cancer of cervix, vagina, vulva, penis, ano-genital and non-genital oro-pharyngeal sites. HPV being a sexually transmitted virus infects both genders equally but with higher chances of pathological outcome in women. In the absence of organized screening programs, women report HPV-infected lesions at relatively advanced stages where they are subjected to standard treatments that are not HPV-specific. HPV infection-driven lesions usually take 10–20 years for malignant progression and are preceded by well-characterized pre-cancer stages. Despite availability of window for pharmacological intervention, therapeutic that could eradicate HPV from infected lesions is currently lacking. A variety of experimental approaches have been made to address this lacuna and there has been significant progress in a number of lead molecules which are in different stages of clinical and pre-clinical development. Present review provides a brief overview of the magnitude of the problem and current status of research on promising lead molecules, formulations and therapeutic strategies that showed potential to translate to clinically-viable HPV therapeutics to counteract this reproductive health challenge
This document discusses the relationship between preterm birth, antibiotics, and cerebral palsy. It summarizes several studies and reviews on this topic. The main points are:
1) Prescribing antibiotics to women in preterm labor has unclear effects, with some evidence it may increase the risk of cerebral palsy and functional impairment in children.
2) For women with preterm premature rupture of membranes (PPROM), antibiotics reduce some short-term risks but do not improve long-term outcomes or reduce cerebral palsy rates.
3) More research is still needed to fully understand the impacts of antibiotic use in preterm labor and how it relates to cerebral palsy and child development.
This Cochrane review evaluated the effects of magnesium sulfate treatment for women at risk of preterm birth to protect the fetus. The review found that magnesium sulfate treatment significantly reduced the risk of cerebral palsy in preterm infants and substantial gross motor dysfunction. There was no significant effect on pediatric mortality or other neurological impairments. Magnesium sulfate treatment was associated with minor side effects in mothers but no significant effects on major maternal complications. The review concluded that magnesium sulfate treatment for women at risk of preterm birth provides neuroprotection for the fetus.
Repeat steroids when is it okay review 2012 ron wapnerAsha Reddy
This document discusses the history and efficacy of antenatal corticosteroids in managing preterm birth. It notes that while antenatal corticosteroids have been shown to significantly reduce neonatal mortality and morbidity rates, questions remain about their efficacy in specific patient populations and safety with repeat courses. The history demonstrates how clinical practices can be adopted before sufficient evidence is available and how arbitrary choices can become standardized. Further research is still needed to determine optimal dosing schedules and administration in special cases.
El plan promueve la inclusión, la igualdad y el respeto de los derechos humanos en materia de salud sexual y salud reproductiva en Ecuador. Establece lineamientos estratégicos y acciones para mejorar indicadores prioritarios como la mortalidad materna, el uso de anticonceptivos y la fecundidad entre adolescentes. Además, articula la gestión del sistema de salud para producir conocimiento sobre este tema e implementar estrategias que logren modificar dichos indicadores.
Este documento describe los mecanismos del parto, incluyendo la situación, presentación, actitud y variedad de posición del feto, los planos de Hodge, el desprendimiento y rotación externa de la cabeza fetal, y los signos de descenso de la placenta.
Este documento presenta una guía de práctica clínica sobre hipertensión arterial desarrollada por el Ministerio de Salud Pública del Ecuador. La guía provee recomendaciones sobre prevención, diagnóstico, tratamiento y seguimiento de pacientes hipertensos. El objetivo es asistir a profesionales de la salud en la toma de decisiones sobre esta condición. La guía fue adaptada de lineamientos internacionales mediante un proceso que incluyó revisión de evidencia y consenso de expertos.
Este documento presenta el Modelo de gestión de aplicación del consentimiento informado en la práctica asistencial, de acuerdo con el Acuerdo Ministerial 5316. Explica la importancia del consentimiento informado, los modelos de relación médico-paciente, y extractos de normas relacionadas con el consentimiento informado en Ecuador. Además, resume los objetivos, condiciones y responsables del proceso de consentimiento informado, y provee un modelo de formulario de consentimiento informado escrito.
Gp tuberculosis 1 / https://www.salud.gob.ec/guias-de-practica-clinica/Jaime Zapata Salazar
Guía de práctica clínica Tuberculosis
Prevención, diagnóstico , tratamiento y control de Tuberculosis
https://www.salud.gob.ec/guias-de-practica-clinica/
Esta guía de práctica clínica del Ministerio de Salud Pública del Ecuador tiene como objetivo proporcionar recomendaciones para la prevención, diagnóstico y tratamiento de la enfermedad renal crónica. Fue desarrollada por un equipo multidisciplinario de expertos y revisada por pares. La guía resume las principales evidencias científicas disponibles sobre la enfermedad renal crónica y ofrece orientación para profesionales de la salud sobre el manejo clínico de esta patología.
El resumen describe los principales cambios en las recomendaciones de 2019 de la Guía de la Asociación Americana de Diabetes sobre el tratamiento y atención de la diabetes. Entre los cambios se incluyen: preferir un agonista del receptor del péptido similar al glucagón en lugar de insulina para pacientes con diabetes tipo 2 que requieren medicamentos inyectables; limitar el beneficio adicional del autocontrol rutinario de glucosa para pacientes con diabetes tipo 2 que no usan insulina; y enfatizar la evaluación del riesgo cardiovascular, la ingesta de agua y
Este documento presenta una guía de práctica clínica sobre la prevención, diagnóstico y tratamiento de la infección por VIH en embarazadas, niños, adolescentes y adultos en Ecuador. La guía fue desarrollada por el Ministerio de Salud Pública a través de un proceso de adaptación de guías internacionales y consenso nacional, con el objetivo de orientar a los profesionales de la salud en la atención clínica de estas poblaciones. La guía incluye recomendaciones actualizadas sobre prevención
Este documento presenta una guía de práctica clínica sobre hipertensión arterial desarrollada por el Ministerio de Salud Pública de Ecuador. La guía define hipertensión arterial, explica su fisiopatología e historia natural, y establece recomendaciones para la prevención, detección, diagnóstico y tratamiento basadas en evidencia científica. La guía busca asistir a profesionales de la salud y pacientes en la toma de decisiones sobre el manejo clínico de la hipertensión.
Esta guía de práctica clínica trata sobre la encefalopatía hipóxica isquémica en recién nacidos y contiene información sobre: 1) la clasificación, diagnóstico diferencial y fisiopatología de esta condición; 2) los aspectos metodológicos considerados en la guía; y 3) las evidencias y recomendaciones para el manejo clínico de los pacientes. La guía fue desarrollada por el Ministerio de Salud Pública del Ecuador y varios hospitales del país con el objetivo de prove
Este documento presenta el protocolo Score MAMÁ y claves obstétricas desarrollado por el Ministerio de Salud Pública de Ecuador. Incluye la herramienta Score MAMÁ para evaluar signos vitales y nivel de conciencia en mujeres embarazadas o puérperas, así como claves de color (roja, azul y amarilla) para la clasificación y manejo de emergencias obstétricas. El objetivo es estandarizar la atención prehospitalaria y de primer nivel para la detección temprana y referencia oportuna de complic
Este documento presenta información sobre la mortalidad materna en Ecuador. Las metas nacionales buscan reducir la razón de mortalidad materna a 40 por cada 100,000 nacidos vivos para el 2017. Se describen las principales causas de muerte materna y se enfatiza la importancia de la planificación familiar y la atención obstétrica de calidad para prevenir estas muertes. Finalmente, se propone la estrategia "Alarma Materna" para mejorar la detección oportuna de complicaciones y la derivación a un nivel de atención adecuado
Este documento presenta el protocolo para el diagnóstico y certificación de la muerte encefálica en Ecuador. Describe los criterios neurológicos para realizar el diagnóstico, incluyendo un examen clínico sistemático y riguroso que confirme la ausencia de reflejos del tronco cerebral y respiración espontánea. También establece la importancia de contar con médicos expertos capacitados para realizar este diagnóstico de gran responsabilidad médico-legal, y la necesidad de disponer de instrumentos normat
Este manual presenta lineamientos para la atención integral de la salud sexual y reproductiva de las personas con discapacidad en Ecuador. Reconoce que históricamente este grupo poblacional ha enfrentado barreras para acceder a estos servicios debido a imaginarios y prácticas que los infantilizan o los consideran asexuados. El documento identifica barreras sociales, culturales, de comunicación, arquitectónicas y de equipamiento, y propone mecanismos para superarlas. También presenta consideraciones generales y lineamientos específicos
Este manual presenta los principios y procedimientos para la gestión de la asistencia humanitaria internacional en situaciones de emergencia y desastre en Ecuador. Detalla las entidades involucradas como la Secretaría de Gestión de Riesgos y el Ministerio de Relaciones Exteriores, y explica los escenarios en los que Ecuador puede participar como país receptor, asistente o facilitador de cooperación internacional. Además, incluye flujogramas y protocolos para coordinar de manera efectiva la ayuda entre los diferentes actores durante una emergencia.
Este documento provee una guía integral para la investigación en salud. Explica los principios básicos y métodos de investigación cualitativa y cuantitativa, y destaca la importancia de los principios éticos en todo el proceso de investigación. Además, brinda referencias actualizadas para aquellos interesados en aprender más sobre los temas cubiertos.
Esta guía de práctica clínica proporciona evidencias y recomendaciones sobre la transfusión de sangre y sus componentes como concentrados de glóbulos rojos, concentrados de plaquetas y plasma fresco congelado. La guía fue desarrollada por un equipo multidisciplinario de expertos en Ecuador con el objetivo de asistir a médicos en la toma de decisiones sobre la transfusión de sangre. La guía incluye definiciones de los componentes de la sangre, recomendaciones para diferentes indicaciones clínicas como cirugía
La Unión Europea ha propuesto un nuevo paquete de sanciones contra Rusia que incluye un embargo al petróleo. El embargo prohibiría la importación de petróleo ruso a la UE y también impediría el acceso de buques rusos a puertos europeos. Sin embargo, Hungría se opone firmemente al embargo al petróleo, argumentando que su economía depende en gran medida de las importaciones de energía rusa.
Esta guía presenta recomendaciones sobre el diagnóstico, manejo y tratamiento de las anomalías de inserción placentaria como la placenta previa, el acretismo placentario y la vasa previa. Proporciona una clasificación de estas condiciones y discute factores de riesgo, manifestaciones clínicas, diagnóstico, manejo prenatal, tratamiento específico y criterios de referencia. El objetivo es asistir a los profesionales de la salud en la toma de decisiones sobre el manejo de estas patologías obstétricas.
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Our backs are like superheroes, holding us up and helping us move around. But sometimes, even superheroes can get hurt. That’s where slip discs come in.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...Donc Test
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
2. Background
Babies born preterm have a higher chance of dying in
the first few weeks of life than those born at term [1].
Babies who survive have a greater risk of neurologic
impairments, such as cerebral palsy, blindness, deafness,
or cognitive dysfunction, and a greater risk of substantial
disability as a result of these neurologic impairments
[2-4]. The social and economic long-term costs are
considerable [5].
Cerebral palsy is a term which includes a number of
different diseases or conditions that can arise at any time
during brain development. It involves a disorder of
movement or posture, or both, and a disorder of motor
function that is permanent but may change over time
[6]. The cerebral palsies remain the most frequent
cause of severe motor disability in childhood with a
background prevalence of two per thousand live births
[6]. Most affected children (92%) survive to 20 years
or later, yielding a substantial burden of illness into
adulthood [7].
Very preterm birth (less than 34 weeks) is the principal
risk factor for cerebral palsy [8,9], responsible for 17%
to 32% of all cases of cerebral palsy. The latest
Australian Cerebral Palsy Register Report (2009)
shows that approximately 45% of all cases of cerebral
palsy are associated with preterm birth [10]. Whilst
the highest risks are for extremely preterm infants
[3], babies born between 30 and 33 completed weeks’
gestation still have significant risks [11] with the risk
of cerebral palsy being up to eight times more likely
than babies born at term [4]. Moderate prematurity is
responsible for as many cases of cerebral palsy as extreme
prematurity [10].
At present there is no cure for cerebral palsy, which
makes effective preventative interventions of paramount
importance. Prevention of cerebral palsy has been
identified by consumers, clinicians and researchers as
a top priority for research by the Australian Cerebral
Palsy Institute [12]. To reduce the impact of cerebral
palsy from preterm birth, efforts must be focused on
primary prevention.
Observational studies on the effect of antenatal
magnesium sulphate on neurodevelopment
A landmark case–control study 15 years ago described
the association of exposure to antenatal magnesium
sulphate with a dramatic reduction in the risk of cerebral
palsy (odds ratio (OR) 0.14; 95% confidence interval (CI)
0.05 to 0.51) [13]. Other observational studies support
a reduction in cerebral palsy in preterm babies after
antenatal magnesium sulphate [14-16] and some a
reduction in the risk of intraventricular hemorrhage
(IVH) [16,17] and perinatal mortality [18]. However, not
all studies report benefit for antenatal magnesium sulphate
on the risk of IVH [19-21], cerebral palsy [20,22,23] or
perinatal mortality [19].
Biological plausibility for use of magnesium sulphate for
fetal and infant neuroprotection
In humans, magnesium is essential for key cellular
processes, including glycolysis, oxidative phosphorylation,
protein synthesis, DNA and RNA aggregation and
maintenance of plasma membrane integrity [24,25].
Magnesium favourably affects mechanisms implicated in
cell death by decreasing proinflammatory cytokines or free
radicals produced during hypoxic-ischaemic reperfusion
and inflammatory diseases of pregnancy [26,27]. Magne-
sium prevents excitotoxic calcium-induced injury [28], by
a non-competitive voltage-dependent inhibition of the
N-methyl-D-aspartate receptor to glutamate reducing
calcium entry into the cell [29]. The fetal and neonatal
brain seems more susceptible to glutamate damage.
Consequently, blocking glutamate receptors through
agents such as magnesium sulphate may reduce the risk
of injury in the perinatal period. Magnesium has some
beneficial haemodynamic effects including stabilising
blood pressure during the first two days of life in preterm
neonates [30], and may increase cerebral blood flow by
reducing constriction of the cerebral arteries [31].
Transplacental transfer of magnesium is rapid with
magnesium concentrations increased in fetal serum within
one hour of maternal intravenous administration [32].
Maternal and neonatal adverse effects and side effects of
magnesium sulphate
The best available evidence about potential maternal
harms from antenatal magnesium sulphate administration
comes from the four Cochrane reviews that compare
magnesium sulphate with placebo or no treatment
[33-36]. Magnesium sulphate, by its peripheral vasodilator
effects when infused intravenously, produces a sensation
of warmth and flushing. Reported maternal side-effects,
related to dosage and speed of infusion, include nausea,
vomiting, headache and palpitations. Hypotension and
respiratory depression are more severe recognised risks.
Magnesium sulphate acts as a neuromuscular blocking
agent that causes abolition of tendon reflexes [37].
Magnesium could aggravate the cardiovascular or neuro-
muscular side-effects of other drugs such as betamimetics,
calcium-channel blockers and gentamicin [38,39]. Infusion
to concentrations above the recommended therapeutic
range can have life threatening consequences for the
women that include respiratory arrest and cardiac arrest
leading to death [40]. For the neonate, hypermagnesaemia
can lead to hyporeflexia, poor sucking, and, rarely, respira-
tory depression needing assisted ventilation [41,42].
Crowther et al. BMC Pregnancy and Childbirth 2013, 13:91 Page 2 of 9
http://www.biomedcentral.com/1471-2393/13/91
3. How antenatal magnesium sulphate can reduce the
burden of being born preterm
Systematic review of randomized trials of magnesium
sulphate for neonatal neuroprotection
The updated Cochrane systematic review to assess the
use of antenatal magnesium sulphate for women at risk
of preterm birth [33] included four trials (4446 babies)
where magnesium sulphate had been given specifically
for neuroprotection of the fetus; two from the US; the
MagNet Trial [43] and the BEAM Trial [44], one from
Australia and New Zealand; the ACTOMgSO4 Trial
[45], one from France; the PreMag Trial [46]. There was
diversity in the inclusion and exclusion criteria for the
four included trials with wide variation in gestational
age, reasons women were at risk of preterm birth and
time of treatment prior to expected preterm birth [33].
All trials used intravenous magnesium sulphate although
the dose used, whether a maintenance infusion was
given and whether treatment could be repeated varied
between trials.
Results of the meta-analysis of the Cochrane systematic
review
The combined outcome of death or cerebral palsy or
cerebral palsy alone showed significant reductions where
women who were at risk of preterm birth were given
magnesium sulphate antenatally with the intent of
providing neuroprotection (Table 1). The review showed
that 63 babies (95% CI 44 to 155) need to be treated
with magnesium sulphate for one baby to avoid cerebral
palsy. The corresponding number needed to treat to
benefit (NNTB) for combined death or cerebral palsy
was 42 babies, 95% CI 24 to 346.
Is there clinical evidence for the role of antenatal
magnesium sulphate for neuroprotection of the fetus,
infant and child prior to preterm birth at 30 to 34 weeks
gestation?
The Australian and New Zealand Bi-national Clinical
Practice Guidelines on the use of antenatal magnesium
sulphate prior to preterm birth for neuroprotection of
the fetus, infant and child summarise the evidence
available from the four individual neuroprotective intent
trials within the Doyle 2009 Cochrane Review [33] that
consider gestational age at trial entry and effect of antenatal
magnesium sulphate [47]. All women in the four included
trials were given magnesium sulphate before 34 weeks’
gestation. In Rouse 2008, all women were less than
32 weeks at trial entry with the majority (68% of trial
participants) less than 30 weeks gestation [44]. Subgroup
analyses for women at different gestational ages were
possible for women with a gestational age of less than
34 weeks, less than 33 weeks, less than 32 weeks and
less than 30 weeks. However there was only one trial
within each subgroup available for analysis and the results
are inconclusive due to small sample sizes (Table 2).
Summary of CPG evidence statement judgements for
gestational age subgroup
The subgroup analyses are from trials with low risk of
bias, with results between trials fairly consistent. While
the evidence is applicable to the Australian and New
Zealand context, generalisability was reduced as the
majority of the women (87%) in the largest trial [44] had
PPROM and so represent a limited subset of women at
risk of preterm birth. Overall clinical impact was judged
to be very large (Table 2) but any differences in death
and cerebral palsy by gestational age are unclear at
present. To minimise the number of women exposed,
the Australian and New Zealand clinic practice guideline
panel felt it would be prudent to restrict magnesium
sulphate administration to the subgroup containing the
lowest gestational age (less than 30 weeks).
Recommendations made by the Australian and New
Zealand Bi-National CPG panel for use of antenatal
magnesium sulphate
The main clinical recommendation is to use magnesium
sulphate for neuroprotection of the fetus, infant and
child “in women at risk of early preterm (gestational age
is less than 30 weeks), imminent birth (when early
preterm birth is planned or definitely expected within
24 hours)” [47].
In recognition of the need for further research, the
guideline panel specifically recommended that further
randomised trials were needed, comparing antenatal
magnesium sulphate with placebo when given to women
at risk of preterm birth at 30 weeks’ gestation or more,
Table 1 Magnesium sulphate vs placebo/no treatment: primary outcomes [33]
Primary outcomes RR, 95% CI Number of trials; participants
Death or cerebral palsy 0.85, 0.74 to 0.98* four trials; 4446 infants
Death (fetal and later) 0.95, 0.80 to 1.12 four trials; 4446 infants
Cerebral palsy 0.71, 0.55 to 0.91* four trials; 4446 infants
Any neurological impairment 1.03, 0.87 to 1.21 one trial; 1255 infants
Death or substantial gross motor dysfunction 0.84, 0.71 to 1.00 three trials; 4387 infants
*Significantly in favour of magnesium sulphate.
Crowther et al. BMC Pregnancy and Childbirth 2013, 13:91 Page 3 of 9
http://www.biomedcentral.com/1471-2393/13/91
4. that assess mortality, cerebral palsy and combined death
and cerebral palsy [47].
Preventative strategies that may reduce the risk of
cerebral palsy need appropriate evaluation prior to
introduction into clinical practice. Given the magnitude
of the protective effect in the systematic review, the
ongoing uncertainty about benefits at later gestational
ages, the serious health and cost consequences of this
condition for the child, family and society a trial of
magnesium sulphate for women at risk of preterm birth
between 30 to 34 weeks’ gestation is both justifiable
and needed.
Aims and objectives of this trial
The aim of this randomised controlled trial is to assess
whether giving magnesium sulphate compared with
placebo to women immediately prior to preterm birth
between 30 and 34 weeks’ gestation reduces the risk of
death or cerebral palsy in their children at two years’
corrected age.
Hypotheses
The primary hypothesis is that antenatal magnesium
sulphate compared with placebo given to women at risk
of preterm birth between 30 and 34 weeks’ gestation
when birth is imminent (defined as planned or definitely
expected in the next 24 hours) reduces the risk of death or
cerebral palsy in their children at two years’ corrected age.
The secondary hypotheses are that antenatal magnesium
sulphate compared with placebo given to women at risk
of preterm birth between 30 and 34 weeks’ gestation when
birth is imminent (defined as planned or definitely
expected in the next 24 hours) above has benefits relating
to the infant/child: including individual components of
the primary outcome (mortality and cerebral palsy), and
neonatal and childhood morbidity (including IVH and the
other neurosensory disabilities at two years’ corrected age
of blindness, deafness or developmental delay). At the
same time, it is hypothesized that the intervention does
not harm the mother: no clinically important effect on
mode of birth or maternal morbidity as measured by risk
of serious adverse cardiovascular effects of the infusion,
side effects of the infusion and postpartum haemorrhage.
Methods/design
Ethics statement
Ethics approval was granted by the Children’s Youth
and Women’s Health Services Human Research Ethics
Committee at the Women’s and Children’s Hospital
(REC2303/8/13) and by the local institutional review
boards for each centre.
Study design
Randomised, multicentre, placebo controlled trial.
Inclusion criteria
Women are eligible for the trial if they are at risk of
preterm birth between 30 to 34 weeks’ gestation where
birth is planned or definitely expected within 24 hours,
have a singleton or twin pregnancy, no contraindications
to the use of antenatal magnesium sulphate (respiratory
depression, hypotension, renal failure, myasthenia gravis)
and give informed, written consent.
Exclusion criteria
Women are not eligible if they have a higher-order
multiple pregnancy, have received antenatal magnesium
sulphate in the current pregnancy or if magnesium
sulphate therapy is considered essential for the treatment
of pre-eclampsia [36].
Trial entry
Eligible women are given the trial information sheet,
counselled by a member of the research team and
encouraged to discuss the study with family before
consent is sought.
Study groups
Once all entry details are given and eligibility is confirmed,
the woman is randomised by contacting the central
telephone randomisation service at the University of
Adelaide. Assignment to one of two study groups: either
the magnesium sulphate group or the placebo group will
be stratified for collaborating centre, gestational age (30 to
31 completed weeks; 32–33 completed weeks’ gestation),
and number of fetuses (1 or 2). A Study Number is
allocated to the woman corresponding to a treatment
Table 2 Results of primary outcomes by gestational age subgroup [33]
Trial N Eligible
(GA wks)
DEATH or CP CP DEATH
RR, 95% CI RR, 95% CI RR, 95% CI
MagNetǂ
[43] 59 >24 to <34 4.83, 0.60 to 38.90 6.77, 0.37 to 125.65 1.93, 0.19 to 20.18
Marret[46] 688 viable to <33 0.80, 0.58 to 1.10 0.70, 0.41 to 1.19 0.85, 0.55 to 1.32
Rouse[44] 2444 24 to <32 0.90, 0.73 to 1.10 0.59, 0.40 to 0.85* 1.13, 0.87 to 1.48
Crowther[45] 1255 <30 0.82, 0.66 to 1.02 0.85, 0.55 to 1.31 0.81, 0.62 to 1.05
Overall 4446 viable to <34 0.85, 0.75 to 0.98* 0.71, 0.55 to 0.91* 0.95, 0.80 to 1.12
ǂ
Neuroprotective arm; CP cerebral palsy; GA gestational age; * statistically significant.
Crowther et al. BMC Pregnancy and Childbirth 2013, 13:91 Page 4 of 9
http://www.biomedcentral.com/1471-2393/13/91
5. pack, each of which looks identical and contains a 100 ml
infusion bag.
Magnesium sulphate study group
Women randomised to the magnesium sulphate study
group are administered 50 ml of a 100 ml infusion
bag containing 8 g magnesium sulphate heptahydrate
[16 mmol magnesium ions] through a dedicated intravenous
infusion line over 30 minutes.
Placebo study group
Women randomised to the placebo study group are
administered 50 ml of a 100 ml infusion bag containing
isotonic sodium chloride solution (0.9%) through a
dedicated intravenous infusion line over 30 minutes.
Both study groups
The woman’s pulse, blood pressure and respiratory rate are
assessed and recorded before the infusion is commenced,
fifteen minutes after the infusion has started and at the end
of the infusion. Any other monitoring as per the individual
obstetric unit protocols for intravenous administration of
magnesium sulphate is followed. Magnesium toxicity is
unlikely with the regimen recommended in this protocol
and serum magnesium concentrations do not need to
be routinely measured. There is a potential theoretical
interaction between magnesium sulphate and nifedipine
of hypotension and neuromuscular blockade effects, al-
though this is seldom reported in clinical practice [38,39].
The trial treatment infusion should be stopped if the
respiratory rate decreases more than four breaths per
minute below baseline, or is less than 12 breaths per
minute; or diastolic blood pressure decreases more than
15 mmHg below baseline level [47]. The infusion may be
continued when the respiratory rate or the blood pressure
return to the baseline levels. Should hypotension or
respiratory depression occur, prompt medical review
is recommended. If there is clinical concern over
respiratory depression calcium gluconate (1 g [10 ml of
10% solution] can be given slowly via the intravenous
route over 10 minutes). Resuscitation and ventilatory
support should be immediately available, if needed, during
administration of the study medication. At the end of the
trial treatment infusion, the section on maternal side
effects should be completed on the Treatment form.
Care during labour and the postnatal stay will be
managed by the obstetric team caring for the woman.
Care of the neonate is the responsibility of the attending
neonatologist.
Follow up after birth until the time of primary discharge
for both groups
The pregnancy and labour data will be extracted from
case notes by the masked research assistant at the
collaborating hospitals. The postnatal and neonatal data
will be collected similarly after discharge of the mother
and baby from hospital.
Longer term follow up
Women enrolled in the trial will give consent for follow-up
of their children from birth until two years’ corrected age
at the time of the initial, prenatal recruitment. Mothers of
all babies discharged home alive will be contacted by a
member of the study team from the coordinating centre
at The University of Adelaide by mail soon after hospital
discharge and then again when their baby is six, 12 and
18 months corrected age. Mothers will be provided with a
reply paid envelope and asked to confirm their current
contact details by mail. At each of these times, a member
of the study team at the coordinating centre will contact
the parents by telephone if a response has not been
received in the mail.
Two years assessments
All surviving children will be formally assessed at two
years of age, corrected for prematurity, by a developmental
paediatrician and psychologist or other assessor trained to
administer the Bayley Scales. All assessors will remain
blinded to treatment group assignment. Assessments will
be made of health, neurodevelopment, behaviour, growth
and blood pressure. This format of assessment has been
used in our previous trials [45,48]. Although cerebral palsy
may not remain a stable diagnosis before five years of age
[49], a diagnosis of severe cerebral palsy (defined below) at
two years of age is unlikely to change subsequently [50].
Gross Motor Function: The paediatric assessment will
include a neurological examination to diagnose cerebral
palsy (abnormality of tone with motor dysfunction) and
other disability outcomes according to previously reported
criteria [51]. Gross Motor Function will be assessed using
the Gross Motor Function Classification System (GMFCS)
level 0 to 5 [52].
Psychological Assessments: The psychological assessment
will include the cognitive, motor and language scales
of the Third Edition of the Bayley Scales of Infant
Development (BSID-III) [53]. This is well-standardised
with demonstrated validity and reliability. Psychological
test scores will be recorded as standardised scores [derived
from raw test scores - mean/standard deviation (SD)].
Children with severe developmental delay who are unable
to complete the psychological assessment will be given a
standardised score of 4 SD below the mean.
Behaviour: The child's caregiver will be asked to
complete the child behaviour checklist [54].
General Health, Health Resource Utilisation, Blood
Pressure and Body Size: A general history and physical
examination will determine the presence of any significant
chronic illness, and data regarding hospital readmissions
Crowther et al. BMC Pregnancy and Childbirth 2013, 13:91 Page 5 of 9
http://www.biomedcentral.com/1471-2393/13/91
6. will be confirmed, where necessary, from the admitting
hospital or doctor. Children will be considered blind if
visual acuity in both eyes is worse than 6/60. Children will
be considered deaf if their hearing loss is sufficient to
require hearing aid(s), or worse.
Blood pressure will be measured and converted to
Z-scores relative to American data for blood pressure for
age, height and gender in childhood [55].
Questionnaires will be completed by the child's caregiver
about any respiratory morbidity, history of illness or injury
and use of health services since primary hospitalisation
(Parent/Caregiver Questionnaire).
The child's height, weight, and head circumference will
be measured in the standard way, and values for the
relevant centile, percent of median, and standard deviation
scores (Z scores) specific for age and gender will be
computed from the British Growth Reference [56].
Categorisation of neurosensory disability
Children will be considered to have a neurosensory
impairment if they have cerebral palsy, GMFCS level
1 to 5, blindness, deafness any of the Bayley Scale
scores more than 1 SD below the mean (<−1SD). The
neurosensory disabilities imposed by the various neuro-
sensory impairments will be classified as severe, moderate
or mild [51] (Table 3).
Primary study endpoints
The primary study endpoint measured in the children at
two years’ corrected age is the combined incidence of death
or cerebral palsy defined as stillbirths, death of live born
infant before hospital discharge or death after hospital
discharge before two years’ corrected age; or any cerebral
palsy [abnormality of tone with motor dysfunction].
Secondary study endpoints
For the infant
Health outcomes considered to be important
measures of mortality and morbidity prior to
primary hospital discharge; (defined as stillbirth and
death of liveborn infant before hospital discharge;
IVH, severe IVH, cystic PVL, neonatal
encephalopathy, neonatal convulsions, proven
necrotising enterocolitis, retinopathy of prematurity
needing treatment, patent ductus arteriosus needing
treatment, respiratory distress syndrome, severity of
any neonatal lung disease, chronic lung disease
(oxygen dependent at 36 weeks post-menstrual age
or 28 days of life if born after 32 weeks gestation),
use of respiratory support, airleak requiring
drainage, confirmed infection within the first
48 hours, infection after the first 48 hours, body size
at birth (weight, length, head circumference) and at
discharge home).
Composite serious health outcome (defined as
stillbirth and death of liveborn infant before hospital
discharge severe respiratory disease, severe
intraventricular haemorrhage (grade 3 4); chronic
lung disease (oxygen dependent at 36 weeks post-
menstrual age or 28 days of life if born after 32 weeks
gestation); proven necrotising enterocolitis; severe
retinopathy of prematurity (Stage 3 or worse in the
better eye); cystic periventricular leukomalacia).
For the child
Key health outcomes assessed at two years’ corrected age:
Individual components of the primary outcome
including severity of cerebral palsy (defined as death;
cerebral palsy).
Death or any neurosensory disability (death defined
as stillbirth, death of live born infant before hospital
discharge or death after hospital discharge; and any
neurosensory disabilities that includes the
neurosensory impairments of cerebral palsy,
[GMFCS level 1 to 5], blindness [corrected visual
acuity worse than 6/60 in the better eye], deafness
[hearing loss requiring amplification or worse], and
any developmental delay defined as standardised
score more than 1 SD below the mean ( −1SD).
Death or major neurosensory disability. Major
neurosensory disability includes severe and moderate
disability (defined as any of: legal blindness,
sensorineural deafness requiring hearing aids;
moderate or severe cerebral palsy [GMFCS level 2
to 5] or developmental delay/intellectual impairment
[standardised score more than two SD below
the mean].
Table 3 Neurosensory Disability Classifications [51]
Severe Disability Any severe cerebral palsy (child
non-ambulant and likely to remain
so; GMFCS level 4 or 5), severe
developmental delay (standardised
score −3 SD) or blindness.
Moderate Disability Moderate cerebral palsy (child
non-ambulant at 2 years of age but
who is likely to ambulate
subsequently; GMFCS level 2 or 3),
or deafness, or moderate
developmental delay (standardised
score from −3 SD to −2 SD).
Mild Disability Mild cerebral palsy (child walking at
2 years of age with only minimal
limitation of movement (GMFCS
level 1), or suspect developmental
delay (standardised score from
−2 SD to −1 SD).
No Neurosensory Disability Children without any neurosensory
impairment.
Crowther et al. BMC Pregnancy and Childbirth 2013, 13:91 Page 6 of 9
http://www.biomedcentral.com/1471-2393/13/91
7. General health of the child (including use of health
services since primary hospitalisation), childhood
respiratory morbidity, blood pressure (Z scores and
proportions in hypertensive ranges), behaviour as
assessed by the Child Behaviour Checklist [54] and
body size.
For the mother
Maternal serious adverse cardiovascular and/or
respiratory outcome of the infusion (defined as
maternal death, cardiac arrest, respiratory arrest).
Maternal side effects of the infusion (including
nausea; vomiting; flushing, infusion arm discomfort;
mouth dryness; sweating; dizziness; blurred vision;
respiratory rate decreased four breaths per minute
below baseline or 12 breaths per minute; blood
pressure decreased 15 mmHg below baseline level;
whether the infusion is discontinued because of
side effects).
Incidence of postpartum haemorrhage, estimated
blood loss at birth 500 ml or more; and major
postpartum haemorrhage, estimated blood loss
1500 ml or more; mode of birth.
Sample size
The rate of our primary outcome of death or cerebral
palsy at two years’ corrected age in an Australian/New
Zealand population between 30 to 34 weeks’ gestation is
estimated to be 9.6%, using a predicted mortality rate up
to 2 years of age of 4.4% (excluding lethal anomalies)
[57] and a predicted rate of cerebral palsy in survivors of
5.2% [46,48].
A trial of 1676 children (838 per group), allowing for a
design effect of 1.2 for clustering of babies within
mothers and a 5% loss to follow up, with an absolute risk
difference of 4.2% [45,46,48] will have 80% power to
detect a statistically significant difference at an alpha
level of 0.05 (two-tailed) of a decrease in the combined
outcome of death or cerebral palsy from 9.6% to 5.4%
with magnesium sulphate compared with placebo.
Analysis and reporting of results
Data will be analysed by a statistician independent of the
clinical investigators. Potential confounding variables will
comprise socio-demographic variables, such as ethnicity,
language spoken at home, family structure, mother’s
marital status, social class, and mother’s and father’s
education, as well as gender of the baby. Comparisons will
be made between treatment groups for the primary and
secondary endpoints using an intention to treat approach.
Analyses will make adjustments for the stratification
variables and for important baseline predictors including
gestational age at birth, and reasons for risk of preterm
birth. Log binomial regression and linear regression will be
used to examine dichotomous and continuous outcomes
respectively with results presented as relative risks or
differences in means along with 95% confidence intervals.
Adjustment till be made for clustering due to multiple
births for infant outcomes using generalized estimating
equations. P-values 0.05 will be considered statistically
significant.
Discussion
The MAGENTA randomised trial assessing the use of
antenatal magnesium sulphate in women at risk of preterm
birth between 30 to 34 weeks’ gestation for neuroprotection
of their infants is important and relevant for clinical
practice globally.
Abbreviations
CI: Confidence interval; GMFCS: Gross motor function classification system;
IVH: Intraventricular haemorrhage; NNTB: Number needed to treat to benefit;
OR: Odds ratio, PVL, periventricular leukomalacia; SD: Standard deviation.
Competing interests
The authors declare they have no competing interests. This study is funded
through the National Health and Medical Research Council of Australia
(NHMRC) in a 5 year project grant (No. 1022968).
Authors’ contributions
CAC, PFM, DW, PA and RH are all members of the MAGENTA Study Group.
The primary investigator of the MAGENTA Study (CAC) wrote the first draft of
the MAGENTA protocol and prepared the initial draft. All authors were
involved in the development of the design of the study, the protocol
development, have commented on all drafts of the protocol, and have read
and approved the final draft of the protocol.
Author details
1
Australian Research Centre for Health of Women and Babies (ARCH), The
Robinson Institute, The University of Adelaide, Adelaide, Australia. 2
Liggins
Institute, The University of Auckland, Auckland, New Zealand. 3
Department of
Neonatal Medicine, The Women’s and Children’s Hospital, Adelaide, South
Australia, Australia.
Received: 27 March 2013 Accepted: 28 March 2013
Published: 9 April 2013
References
1. ANZNN (Australian and New Zealand Neonatal Network): Report of the
Australian and New Zealand Neonatal Network 2008 and 2009. Sydney:
ANZNN; 2012.
2. Saigal S, Doyle LW: An overview of mortality and sequelae of preterm
birth from infancy to adulthood. Lancet 2008, 371(9608):261–269.
3. Doyle LW, Victorian Infant Collaborative Study Group: Evaluation of
neonatal intensive care for extremely low birth weight infants in Victoria
over two decades: II. Efficiency. Pediatrics 2004, 113(3 Pt 1):510–514.
4. Petrini JR, Dias T, McCormick MC, Massolo ML, Green NS, Escobar GJ:
Increased risk of adverse neurological development for late preterm
infants. J Pediatr 2009, 154(2):169–176.
5. Mangham LJ, Petrou S, Doyle LW, Draper ES, Marlow N: The cost of
preterm birth throughout childhood in England and Wales. Pediatrics
2009, 123(2):e312–317.
6. Oxford Register of Early Childhood Impairment: National Perinatal
Epidemiology Unit, Annual Report. Oxford: Institue of Health Sciences; 2001.
7. Hutton JL, Cooke T, Pharoah POD: Life expectancy in children with
cerebral palsy. Brit Med J 1994, 309(6952):431–435.
8. Drummond PM, Colver AF: Analysis by gestational age of cerebral palsy
in singleton births in north-east England 1970–94. Paediatr Perinat
Epidemiol 2002, 16(2):172–180.
Crowther et al. BMC Pregnancy and Childbirth 2013, 13:91 Page 7 of 9
http://www.biomedcentral.com/1471-2393/13/91
8. 9. Winter S, Autry A, Boyle C, Yeargin-Allsopp M: Trends in the prevalence of
cerebral palsy in a population-based study. Pediatrics 2002, 110(6):1220–1225.
10. ACPR Group: Report of the Australian Cerebral Palsy Register, Birth Years
1993–2003. Sydney: ACPR; Dec 2009.
11. Marret S, Ancel PY, Marpeau L, Marchand L, Pierrat V, Larroque B, Foix-L
'Helias L, Thiriez G, Fresson J, Alberge C, et al: Neonatal and 5-year
outcomes after birth at 30–34 weeks of gestation. Obstet Gynecol 2007,
110(1):72–80.
12. McIntyre S, Novak I, Cusick A: Consensus research priorities for cerebral
palsy: a Delphi survey of consumers, researchers, and clinicians. Dev Med
Child Neurol 2010, 52(3):270–275.
13. Nelson KB, Grether JK: Can magnesium sulphate reduce the risk of
cerebral palsy in very low birthweight infants? Pediatrics 1995, 95:1–1.
14. Hauth JC, Goldenberg RL, Nelson KG, Dubard MB, Peralta MA, Gaudier FL:
Reduction of cerebral palsy with maternal MgSO4 treatment in newborns
weighing 500-1000 g. Am J Obstet Gynecol 1995, 172(1 Pt 2):419.
15. Schendel DE, Berg CJ, YearginAllsopp M, Boyle CA, Decoufle P: Prenatal
magnesium sulfate exposure and the risk for cerebral palsy or mental
retardation among very low-birth-weight children aged 3 to 5 years.
JAMA 1996, 276(22):1805–1810.
16. Wiswell TE, Graziani LJ, Caddell JL, Vecchione N, Stanley C, Spitzer AR:
Maternally-administered magnesium sulfate (MgSO4) protects against
early brain injury and long-term adverse neurodevelopmental outcomes
in preterm infants: A prospective study. Pediatr Res 1996, 39(4):1502.
17. FineSmith RB, Roche K, Yellin PB, Walsh KK, Shen C, Zeglis M, Kahn A, Fish I:
Effect of magnesium sulfate on the development of cystic
periventricular leukomalacia in preterm infants. Am J Perinat 1997,
14(5):303–307.
18. Grether JK, Hoogstrate J, Selvin S, Nelson KB: Magnesium sulfate tocolysis
and risk of neonatal death. Am J Obstet Gynecol 1998, 178(1):1–6.
19. Kimberlin DF, Hauth JC, Goldenberg RL, Bottoms SF, Iams JD, Mercer B,
MacPherson C, Thurnau GR: The effect of maternal magnesium sulfate
treatment on neonatal morbidity in = 1000-gram infants. Am J Perinat
1998, 15(11):635–641.
20. Paneth N, Jetton J, PintoMartin J, Susser M, Clark C, Gardiner J, Holzman C,
Lorenz JM, Reuss ML: Magnesium sulfate in labor and risk of neonatal
brain lesions and cerebral palsy in low birth weight infants. Pediatrics
1997, 99(5):E1.
21. Weintraub Z, Solovechick M, Reichman B, Rotschild A, Waisman D, Davkin O,
Lusky A, Bental Y, Israel Neonatal Network: Effect of maternal tocolysis on
the incidence of severe periventricular/intraventricular haemorrhage in
very low birthweight infants. Arch Dis Child 2001, 85(1):F13–F17.
22. Grether JK, Hoogstrate J, Walsh-Greene E, Nelson KB: Magnesium sulfate
for tocolysis and risk of spastic cerebral palsy in premature children
born to women without preeclampsia. Am J Obstet Gynecol 2000,
183(3):717–725.
23. O'Shea TM, Klinepeter KL, Meis PJ, Dillard RG: Intrauterine infection and
the risk of cerebral palsy in very low-birthweight infants. Paediatr Perinat
Epidemiol 1998, 12(1):72–83.
24. Mildvan AS: Role of magnesium and other divalent cations in ATP-
utilizing enzymes. Magnesium 1987, 6(1):28–33.
25. McIntosh TK, Vink R, Yamakami I, Faden AI: Magnesium protects against
neurological deficit after brain injury. Brain Res 1989, 482(2):252–260.
26. Hoffman DJ, Marro PJ, McGowan JE, Mishra OP, Delivoriapapadopoulos M:
Protective effect of MgSO4 infusion on nmda receptor binding
characteristics during cerebral cortical hypoxia in the newborn piglet.
Brain Res 1994, 644(1):144–149.
27. Shogi T, Miyamoto A, Ishiguro S, Nishio A: Enhanced release of IL-1 beta
and TNF-alpha following endotoxin challenge from rat alveolar
macrophages cultured in low-Mg2+ medium. Magnesium Res 2003,
16(2):111–119.
28. Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A: Magnesium
Gates Glutamate-Activated Channels in Mouse Central Neurons. Nature
1984, 307(5950):462–465.
29. Ovbiagele B, Kidwell CS, Starkman S, Saver JL: Potential Role of
Neuroprotective Agents in the Treatment of Patients with Acute
Ischemic Stroke. Curr Treat Options Cardiovasc Med 2003, 5(6):441–449.
30. Rantonen TH, Gronlund JU, Jalonen JO, Ekblad UU, Kaapa PO, Kero PO,
Valimaki IAT: Comparison of the effects of antenatal magnesium sulphate
and ritodrine exposure on circulatory adaptation in preterm infants. Clin
Physiol Funct Imaging 2002, 22(1):13–17.
31. Macdonald RL, Curry DJ, Aihara Y, Zhang ZD, Jahromi BS, Yassari R:
Magnesium and experimental vasospasm. J Neurosurg 2004,
100(1):106–110.
32. Hallak M, Cotton DB: Transfer of maternally administered magnesium
sulfate into the fetal compartment of the rat. Am J Obstet Gynecol 1993,
169(2):427–431.
33. Doyle L, Crowther C, Middleton P, Marret S, Rouse D: Antenatal
magnesium sulphate and neuroprotection for very preterm infants –
The updated Cochrane review. J Paediatr Child H 2009, 45(suppl 1):A47.
34. Crowther C, Hiller J, Doyle L, Lumley J, Carlin J: Tocolytic magnesium
sulphate and paediatric mortality. Lancet 1998, 351(9098):291–291.
35. Crowther CA, Hiller JE, Doyle LW: Magnesium sulphate for preventing
preterm birth in threatened preterm labour. Cochrane Db Syst Rev 2002
(Issue 4). Art. No.: CD001060. doi:10.1002/14651858.CD001060.
36. Duley L, Gulmezoglu A, Henderson-Smart D: Magnesium sulphate and
other anticonvulsants for women with pre-eclampsia. Cochrane Db Syst
Rev 2003(Issue 2). Art. No.: CD000025. doi:10.1002/1465158.CD000025.
37. Baraka A, Yazigi A: Neuromuscular interaction of magnesium with
succinylcholine-vecuronium sequence in the eclamptic parturient.
Anesthesiology 1987, 67(5):806–808.
38. Snyder SW, Cardwell MS: Neuromuscular blockade with magnesium
sulfate and nifedipine. Am J Obstet Gynecol 1989, 161(1):35–36.
39. Ben-Ami M, Giladi Y, Shalev E: The combination of magnesium sulphate
and nifedipine: a cause of neuromuscular blockade. Br J Obstet Gynaecol
1994, 101(3):262–263.
40. McDonnell NJ: Cardiopulmonary arrest in pregnancy: two case reports of
successful outcomes in association with perimortem Caesarean delivery.
Br J Anaesth 2009, 103(3):406–409.
41. Levene M, Blennow M, Whitelaw A, Hanko E, Fellman V, Hartley R: Acute
effects of two different doses of magnesium sulphate in infants with
birth asphyxia. Arch Dis Child-Fetal 1995, 73(3):F174–177.
42. Lipsitz PJ: The clinical effects of excess magnesium in the newborn.
Pediatrics 1971, 47(3):501–509.
43. Mittendorf R, Dambrosia J, Pryde PG, Lee KS, Gianopoulos JG, Besinger RE,
Tomich PG: Association between the use of antenatal magnesium sulfate
in preterm labor and adverse health outcomes in infants. Am J Obstet
Gynecol 2002, 186(6):1111–1118.
44. Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, Iams JD,
Wapner RJ, Sorokin Y, Alexander JM, et al: A randomized, controlled trial of
magnesium sulfate for the prevention of cerebral palsy. New Engl J Med
2008, 359(9):895–905.
45. Crowther CA, Hiller JE, Doyle LW, Haslam RR, the Australasian Collaborative
Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group: Effect of
magnesium sulfate given for neuroprotection before preterm birth - A
randomized controlled trial. Jama J Am Med Assoc 2003,
290(20):2669–2676.
46. Marret S, Marpeau L, Benichou J: Benefit of magnesium sulfate given
before very preterm birth to protect infant brain. Pediatrics 2008,
121(1):225–226.
47. The Antenatal Magnesium Sulphate for Neuroprotection Guideline
Development Panel: Antenatal magnesium sulphate prior to preterm birth for
neuroprotection of the fetus, infant and child: National clinical practice
guidelines. Adelaide: The University of Adelaide; 2010.
48. Crowther CA, Doyle LW, Haslam RR, Hiller JE, Harding JE, Robinson JS,
ACTORDS Study Group: Outcomes at 2 years of age after repeat doses of
antenatal corticosteroids. New Engl J Med 2007, 357(12):1179–1189.
49. Stanley FJ, Watson L: Trends in Perinatal-Mortality and Cerebral-Palsy in
Western-Australia, 1967 to 1985. BMJ 1992, 304(6843):1658–1663.
50. Paneth N: Establishing the Diagnosis of Cerebral Palsy. Clin Obstet Gynecol
2008, 51(4):742–748.
51. Doyle LW, Victorian Infant Collaborative Study Group: Changing availability
of neonatal intensive care for extremely low birthweight infants in
Victoria over two decades. Med J Aust 2004, 181(3):136–139.
52. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B:
Development and reliability of a system to classify gross motor
function in children with cerebral palsy. Dev Med Child Neurol 1997,
39(4):214–223.
53. Bayley N: Bayley Scales of Infant and Toddler Development (Third Edition). San
Antonio: Harcourt Assessment (PsychCorp); 2006.
54. Achenbach T: Manual for the Child Behaviour Checklist/2-3 and1992 Profile.
Burlington, VT: University of Vermont Department of Psychiatry; 1992.
Crowther et al. BMC Pregnancy and Childbirth 2013, 13:91 Page 8 of 9
http://www.biomedcentral.com/1471-2393/13/91
9. 55. Rosner B, Prineas RJ, Loggie JM, Daniels SR: Blood pressure nomograms for
children and adolescents, by height, sex, and age, in the United States.
J Pediatr 1993, 123(6):871–886.
56. Freeman JV, Cole TJ, Chinn S, Jones PRM, White EM, Preece MA: Cross-
sectional stature and weight reference curves for the UK 1990.
Arch Dis Child 1995, 73(1):17–24.
57. Laws P, Li Z, Sullivan EA: Australia's mothers and babies 2008. Perinatal
statistics series no. 24. Cat. no. PER 50. AIHW: Canberra; 2010.
doi:10.1186/1471-2393-13-91
Cite this article as: Crowther et al.: Magnesium sulphate at 30 to
34 weeks’ gestational age: neuroprotection trial
(MAGENTA) - study protocol. BMC Pregnancy and Childbirth 2013 13:91.
Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit
Crowther et al. BMC Pregnancy and Childbirth 2013, 13:91 Page 9 of 9
http://www.biomedcentral.com/1471-2393/13/91